Oncimmune Demonstrates IP strength with agreement with Dana-Farber
(ONC ) has signed an autoantibody profiling contract with the Dana-Farber Cancer Institute ("Dana-Farber").
Dana-Farber is a world-leading cancer research organisation and one of America's top-rated cancer hospitals with more than 1,100 therapeutic and non-therapeutic clinical trials in progress and a clinical affiliate and research institute of Harvard Medical School, Boston, Massachusetts.
Under today’s agreement, Oncimmune will be utilising its proprietary biomarker discovery engine, SeroTag™, in Dana-Farber led studies or therapies using the latest immunotherapies using atezolizumab, nivolumab, pembrolizumab, durvalumab and cisplatin-based chemotherapy.
Dr Adam M Hill, CEO of Oncimmune said: "We are delighted to be partnering with such a prestigious organisation as Dana-Farber on the use of multiple CPI assets in this important oncology trial and leveraging the power of our autoantibody biomarker profiling technology.
SeroTag™ is Oncimmune's “high-throughput, multiplex, discovery technology” based on its in-house protein library, which is one of the largest in the world, with a unique, ever-growing repository of disease data for indications such as autoimmune and infectious diseases as well as cancer.
The proprietary SeroTag™ immuno-oncology discovery array is based on autoantibody profiling studies in autoimmune diseases and other cancer types and comprises known and proprietary antigens linked to a number of cancers, autoimmune and infectious diseases.
Dr Hill added; “As autoantibodies continue to be recognised as a key biomarker class that aid in the understanding of interactions between cancer and the immune system, the ImmunoINSIGHTS platform is becoming increasingly instrumental in studies for a wide range of cancer indications and therapy classes."
View From Vox
As with any other viruses, a disease’s RNA changes over time to become more resistant to drugs (re lower efficacy). This is where Oncimmune’s propriety immunoINSIGHTs platform plays an invaluable role.
Today’s news of this agreement with a major US oncology centre - Dana-Farber Cancer Institute – demonstrates the strength of the Company‘s IP to profile patients in immuno-oncology trials, using its proprietary biomarker discovery engine, SeroTag™.
Whilst ONC shares have given up some of the gains, in-line with the rest of the sector, over the past three months - investors are still sitting on gains of 20% over a 12 month time frame. Furthermore, the long-term out look for the Company is particularly strong and we would encourage investor to *watch” the latest over view from Dr Adam Hill here.
Oncimmune Holdings’ focus is to harness the immune system’s sophisticated response to disease to detect cancer earlier and to support the development of better therapies.
Leading Proprietary Technology Portfolio
The company believes the key to improving cancer survival is early detection and optimal selection for therapy. Oncimmune's immuno-diagnostic test, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis.
Oncimmune’s core technology also powers its ImmunoINSIGHTS service; a proprietary platform that enables life-science organisations to optimise drug development and delivery, leading to more effective, targeted as well as safer treatments for patients.
The group’s EarlyCDT Lung blood test was previously featured on an ITV news broadcast last weekend titled ‘New Blood Test Provides Breakthrough in Lung Cancer Detection Rates’.
The feature highlighted that, in the UK, more than 35,000 people die of lung cancer each year and most have their lung cancer diagnosed late thereby lowering their chances of survival. 80% of lung cancer cases are diagnosed in the latest stages of the disease.
The EarlyCDT test works to identify the immune system's response to the presence of lung cancer. The test detects antibodies present in the body, enabling clinicians to focus their diagnosis on identifying the disease and treating it earlier than current clinical practice.
It has previously been shown that Oncimmune’s EarlyCDT Lung blood test can detect lung cancer on average four years before standard of care and has shown in a large National Health Service (NHS) trial that it can reduce late stage lung cancer presentation by 36%.
Inflection Point to Commercialisation
The Company now believes it has made the point of inflection as it matures from an R&D business into a commercial entity evidenced through its deepening commercial relationships with Industry Partners such as Roche
The Company is now fully funded to develop all its commercial activities and drive revenues.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.